Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Receivables: 2009-2024

Historic Change in Receivables for Madrigal Pharmaceuticals (MDGL) over the last 6 years, with Dec 2024 value amounting to $53.8 million.

  • Madrigal Pharmaceuticals' Change in Receivables rose 44.52% to $34.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.8 million, marking a year-over-year increase of 173.57%. This contributed to the annual value of $53.8 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Change in Receivables of $53.8 million as of FY2024, which was up 768,985.71% from -$7,000 recorded in FY2016.
  • Madrigal Pharmaceuticals' Change in Receivables' 5-year high stood at $53.8 million during FY2024, with a 5-year trough of $53.8 million in FY2024.
  • In the last 1 years, Madrigal Pharmaceuticals' Change in Receivables had a median value of $53.8 million in 2024 and averaged $53.8 million.